News

It is a gamma-secretase modulator being developed as a potent once-daily oral therapy for the treatment and potential prevention of AD. According to the company, existing therapies approved

The post Acta Pharmaceuticals raises $24m for Alzheimer’s therapies appeared first on Pharmaceutical Business review.

The initiative centres on creating a high-resolution, patient-derived molecular map of the fatal neurodegenerative disorder, which currently has few effective therapies. Under the terms of the agreement, Mayo

The post Transcripta Bio, Mayo Clinic join force on ALS therapies appeared first on Pharmaceutical Business review.

The initial agreement marks the first commercial contract in the pharmaceutical and biotechnology sector for QCi. Under the first stage of the project, the companies will analyse clinical

The post QCi and INmune Bio partner to study XPro in Alzheimer’s appeared first on Pharmaceutical Business review.

Under the agreement, Alentis has secured an exclusive option to in-license linkers and payloads from PinotBio for use in its pipeline candidates. Financially, PinotBio will receive an upfront

The post Alentis and PinotBio partner to develop claudin-1 oncology ADCs appeared first on Pharmaceutical Business review.

The partnership focuses on biologics quality control as well as viral and release testing under current good manufacturing practice (cGMP) standards. Magellan recently completed Phase I/II clinical studies

The post Charles River partners with Magellan Stem Cells on cell therapy appeared first on Pharmaceutical Business review.

Under the partnership, Enodia Therapeutics will handle initial discovery work to identify, refine, and advance small-molecule candidates directed at multiple targets. Pfizer will take full responsibility for subsequent

The post Pfizer partners with Enodia Therapeutics in $500m drug deal appeared first on Pharmaceutical Business review.

The company was informed of the decision by its domestic licensing partner, Changchun GeneScience Pharmaceutical (GenSci). GenSci holds exclusive Chinese commercial rights to Camcevi across all existing and

The post China’s NMPA clears Foresee’s Camcevi 42 mg for prostate cancer appeared first on Pharmaceutical Business review.

The planned facility will focus on the development, validation, and adoption of new approach methodologies (NAMs). These laboratory, computational, and data-oriented methods are designed to mirror human biology

The post Southern Research secures NIH funding for drug testing hub appeared first on Pharmaceutical Business review.

This oral medication is indicated for patients whose infections do not respond, with or without documented resistance, to standard antiviral therapies including acyclovir, famciclovir, or valacyclovir. The company

The post FDA approves Asahi Kasei’s Hovilpri for refractory HSV appeared first on Pharmaceutical Business review.

Under the terms of the agreement, the two companies will direct qualified customer opportunities to the other across the development pipeline. A joint governance structure will oversee the

The post Perceptive, Nucleus partner to support radiopharmaceutical development appeared first on Pharmaceutical Business review.